Moderna’s efforts to develop a range of mRNA vaccines for influenza have been bolstered with funding of up to $750 million from investment firm Blackstone Life Sciences.
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling
In this edition of Deep Dive, delve into the revolutionary world of genetic editing as we trace the development of CRISPR, discover why Alexion’s Soraya Bekkali believes now it the time to champion
Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest